3424-43-9

Basic information

• Product Name: ETHYL 6-HYDROXY-2-METHYLPYRIDINE-3-CARBOXYLATE
• Synonyms: ETHYL 6-HYDROXY-2-METHYLPYRIDINE-3-CARBOXYLATE;ethyl 2-Methyl-6-oxo-1,6-dihydropyridine-3-carboxylate;2-Methyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid ethyl ester;6-Hydroxy-2-methylnicotinic acid ethyl ester
• CAS NO: 3424-43-9
• Molecular Formula: C₉H₁₁NO₃
• Molecular Weight: 181.19
• Product Categories: Heterocycle-Pyridine series
• Mol File: 3424-43-9.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 349.7°C at 760 mmHg
• Flash Point: 165.3°C
• Appearance: /
• Density: 1.163g/cm³
• Vapor Pressure: 4.61E-05mmHg at 25°C
• Refractive Index: 1.503
• Storage Temp.: 2-8°C
• CAS DataBase Reference: ETHYL 6-HYDROXY-2-METHYLPYRIDINE-3-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 6-HYDROXY-2-METHYLPYRIDINE-3-CARBOXYLATE(3424-43-9)
• EPA Substance Registry System: ETHYL 6-HYDROXY-2-METHYLPYRIDINE-3-CARBOXYLATE(3424-43-9)

Safety Data

• Hazardous Substances Data: 3424-43-9(Hazardous Substances Data)

Usage

General Description

ETHYL 6-HYDROXY-2-METHYLPYRIDINE-3-CARBOXYLATE is a chemical compound with the molecular formula C11H13NO4. It is a derivative of pyridine, containing a hydroxy group, a methyl group, and an ethyl ester group. ETHYL 6-HYDROXY-2-METHYLPYRIDINE-3-CARBOXYLATE is commonly used in the synthesis of pharmaceuticals and agrochemicals, and it exhibits potential biological activities such as anti-inflammatory and antioxidant properties. The presence of the ester group makes it suitable for use as a flavor or fragrance ingredient in various consumer products. Additionally, the structure of ETHYL 6-HYDROXY-2-METHYLPYRIDINE-3-CARBOXYLATE makes it a promising candidate for further research and development in the field of medicinal chemistry.

InChI:InChI=1/C9H11NO3/c1-3-13-9(12)7-4-5-8(11)10-6(7)2/h4-5H,3H2,1-2H3,(H,10,11)

Upstream product

• 4027-39-8 2-methyl-6-oxo-1,4,5,6-tetrahydro-pyridine-3-carboxylic acid ethyl ester 
• 1039037-16-5 5-ethyl 1-methyl 4-(1-amino-ethylidene)-pent-2-enedioate 
• 546-67-8 lead(IV) tetraacetate 
• 6296-99-7 diethyl aminomethylenemalonate 
• 141-97-9 ethyl acetoacetate 
• 100643-08-1 (Z)-ethyl 2-(aminomethylene)-3-oxobutanoate 
• 626-34-6 ethyl 3-aminobut-2-enoate 
• 1432-45-7 N-acetyl acrylamide 
• 4341-76-8 Ethyl 2-butynoate 
• 79404-68-5 N-methoxy acrylamide 
• 79-06-1 2-propenamide 
• 53256-25-0 (2E,4Z)-5-ethyl 1-methyl 4-(1-aminoethylidene)pent-2-enedioate 
• 53256-26-1 (E)-4-[1-amino-eth-(Z)-ylidene]-pent-2-enedioic acid diethyl ester 
• 23941-84-6 5-formy-1,3,6-trimethyluracil 

Downstream Products

• 1174665-76-9 5-iodo-2-methyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid ethyl ester 
• 1359669-60-5 C₂₃H₂₁NO₂ 
• 1359669-62-7 diethyl {2-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl}malonate 
• 1359668-78-2 2-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-ol 
• 1359668-80-6 {2-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl}acetic acid 
• 41598-57-6 ethyl 2-chloro-5-oxo-6,7-dihydro-5H-cyclopenta[b]pyridine-6-carboxylate 
• 1227515-71-0 6-methoxy-2-methylnicotinic acid 
• 1196154-17-2 2?methoxy?6,7?dihydro?5H?cyclopenta[b]pyridine?5?one 
• 1430058-83-5 C₂₅H₂₉N₅O₃ 
• 1430058-81-3 C₂₁H₂₄BrN₃O₃ 
• 1430057-55-8 6-[(1S)-2-amino-1-benzylethyl]-2-(1-methyl-1H-pyrazol-5-yl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one 
• 1430057-53-6 6-[(1S)-2-amino-1-(3-fluorobenzyl)ethyl]-2-(4-chloro-1-methyl-1H-pyrazol-5-yl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one 
• 1430058-79-9 2-[(2S)-2-[2-(4-chloro-1-methyl-1H-pyrazol-5-yl)-5-oxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-3-(3-fluorophenyl)propyl]-1H-isoindole-1,3(2H)-dione 
• 1430058-77-7 2-(4-chloro-1-methyl-1H-pyrazol-5-yl)-6-[(1S)-1-(3-fluorobenzyl)-2-hydroxyethyl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one 

Relevant articles and documents

HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF

The present invention relates to a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the treatment of various HAT-related diseases or conditions.

Ru-Catalyzed Regioselective Cascade Annulation of Acrylamides with 2-Alkynoates for the Synthesis of Various 6-Oxo Nicotinic Acid Esters

Ru-catalyzed regioselective cascade annulation of acrylamides with 2-alkynoates via aza-Michael/C-H activation sequence for the synthesis of various 6-oxo nicotinic acid esters is described. The regioselectivity of the protocol has been confirmed by performing silver mediated protodecarboxylation of the corresponding 6-oxo nicotinic acid to furnish 2-pyridone. The developed protocol is copper or silver salt-free and uses inexpensive, safe, and environmentally benign peroxide-based "oxone" as the sole oxidant. A redox-neutral version of the protocol is also demonstrated.

SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE

Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.